Search ACTG publications from 1/1/2006 to current.


Filter results by

Found 92 results
Filters: First Letter Of Last Name is S  [Clear All Filters]
Found 92 results.
Skip Alphabet Links A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  


Saberi P, Neilands TB, Vittinghoff E, Johnson MO, Chesney M, Cohn SE. "Barriers to antiretroviral therapy adherence and plasma HIV RNA suppression among AIDS clinical trials group study participants." AIDS Patient Care STDS. 2015;29(3):111-6.
Sacktor N, Miyahara S, Deng L, et al. "Minocycline treatment for HIV-associated cognitive impairment: results from a randomized trial." Neurology. 2011;77(12):1135-42.
Sacktor N, Miyahara S, Evans S, et al. "Impact of minocycline on cerebrospinal fluid markers of oxidative stress, neuronal injury, and inflammation in HIV-seropositive individuals with cognitive impairment." J. Neurovirol.. 2014;20(6):620-6.
Safren SA, Hendriksen ES, Smeaton L, et al. "Quality of life among individuals with HIV starting antiretroviral therapy in diverse resource-limited areas of the world." AIDS Behav. 2012;16(2):266-77.
Safren SA, Biello KB, Smeaton L, et al. "Psychosocial predictors of non-adherence and treatment failure in a large scale multi-national trial of antiretroviral therapy for HIV: data from the ACTG A5175/PEARLS trial." PLoS ONE. 2014;9(8):e104178.
Saharia KK, Petrovas C, Ferrando-Martinez S, et al. "Tuberculosis Therapy Modifies the Cytokine Profile, Maturation State, and Expression of Inhibitory Molecules on Mycobacterium tuberculosis-Specific CD4+ T-Cells." PLoS ONE. 2016;11(7):e0158262.
Sandler NG, Zhang X, Bosch RJ, et al. "Sevelamer does not decrease lipopolysaccharide or soluble CD14 levels but decreases soluble tissue factor, low-density lipoprotein (LDL) cholesterol, and oxidized LDL cholesterol levels in individuals with untreated HIV infection." J. Infect. Dis.. 2014;210(10):1549-54.
Sattler FR, Rajicic N, Mulligan K, et al. "Evaluation of high-protein supplementation in weight-stable HIV-positive subjects with a history of weight loss: a randomized, double-blind, multicenter trial." Am. J. Clin. Nutr.. 2008;88(5):1313-21.
Sax PE, Komarow L, Finkelman MA, et al. "Blood (1->3)-beta-D-glucan as a diagnostic test for HIV-related Pneumocystis jirovecii pneumonia." Clin. Infect. Dis.. 2011;53(2):197-202.
Sax PE, Tierney C, Collier AC, et al. "Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results." J. Infect. Dis.. 2011;204(8):1191-201.
Sax PE, Sloan CE, Schackman BR, et al. "Early antiretroviral therapy for patients with acute aids-related opportunistic infections: a cost-effectiveness analysis of ACTG A5164." HIV Clin Trials. 2010;11(5):248-59.
Sax PE, Tierney C, Collier AC, et al. "Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy." N. Engl. J. Med.. 2009;361(23):2230-40.
Schacker TW, Bosch RJ, Bennett K, et al. "Measurement of naive CD4 cells reliably predicts potential for immune reconstitution in HIV." J. Acquir. Immune Defic. Syndr.. 2010;54(1):59-62.
Schackman BR, Haas DW, Park SS, X Li C, Freedberg KA. "Cost-effectiveness of CYP2B6 genotyping to optimize efavirenz dosing in HIV clinical practice." Pharmacogenomics. 2015;16(18):2007-18.
Schackman BR, Scott CA, Sax PE, et al. "Potential risks and benefits of HIV treatment simplification: a simulation model of a proposed clinical trial." Clin. Infect. Dis.. 2007;45(8):1062-70.
Schackman BR, Ribaudo HJ, Krambrink A, Hughes V, Kuritzkes DR, Gulick RM. "Racial differences in virologic failure associated with adherence and quality of life on efavirenz-containing regimens for initial HIV therapy: results of ACTG A5095." J. Acquir. Immune Defic. Syndr.. 2007;46(5):547-54.
Schifitto G, Yiannoutsos CT, Simpson DM, et al. "A placebo-controlled study of memantine for the treatment of human immunodeficiency virus-associated sensory neuropathy." J. Neurovirol.. 2006;12(4):328-31.
Schifitto G, Navia BA, Yiannoutsos CT, et al. "Memantine and HIV-associated cognitive impairment: a neuropsychological and proton magnetic resonance spectroscopy study." AIDS. 2007;21(14):1877-86.
Schifitto G, Yiannoutsos CT, Ernst T, et al. "Selegiline and oxidative stress in HIV-associated cognitive impairment." Neurology. 2009;73(23):1975-81.
Schifitto G, Zhang J, Evans SR, et al. "A multicenter trial of selegiline transdermal system for HIV-associated cognitive impairment." Neurology. 2007;69(13):1314-21.
Schifitto G, Deng L, Yeh T-min, et al. "Clinical, laboratory, and neuroimaging characteristics of fatigue in HIV-infected individuals." J. Neurovirol.. 2011;17(1):17-25.
Schnitzer ME, Lok JJ, Bosch RJ. "Double robust and efficient estimation of a prognostic model for events in the presence of dependent censoring." Biostatistics. 2016;17(1):165-77.
Schooley RT, Spritzler J, Wang H, et al. "AIDS clinical trials group 5197: a placebo-controlled trial of immunization of HIV-1-infected persons with a replication-deficient adenovirus type 5 vaccine expressing the HIV-1 core protein." J. Infect. Dis.. 2010;202(5):705-16.
Schouten JThomas, Schiffer JT. "Equal HIV-1 decay kinetics in HSV-2-infected and HSV-2-uninfected clinical trial participants treated with antiretroviral therapy." J. Acquir. Immune Defic. Syndr.. 2012;60(1):68-71.
Schouten JT, Krambrink A, Ribaudo HJ, et al. "Substitution of nevirapine because of efavirenz toxicity in AIDS clinical trials group A5095." Clin. Infect. Dis.. 2010;50(5):787-91.
Schwarze-Zander C, Blackard JT, Zheng H, et al. "GB virus C (GBV-C) infection in hepatitis C virus (HCV)/HIV-coinfected patients receiving HCV treatment: importance of the GBV-C genotype." J. Infect. Dis.. 2006;194(4):410-9.
Seaman WT, Andrews E, Couch M, et al. "Detection and quantitation of HPV in genital and oral tissues and fluids by real time PCR." Virol. J.. 2010;7:194.
Sereti I, Dunham RM, Spritzler J, et al. "IL-7 administration drives T cell-cycle entry and expansion in HIV-1 infection." Blood. 2009;113(25):6304-14.
Servoss JC, Kitch DW, Andersen JW, Reisler RB, Chung RT, Robbins GK. "Predictors of antiretroviral-related hepatotoxicity in the adult AIDS Clinical Trial Group (1989-1999)." J. Acquir. Immune Defic. Syndr.. 2006;43(3):320-3.
Sha BE, Tierney C, Cohn SE, et al. "Postpartum viral load rebound in HIV-1-infected women treated with highly active antiretroviral therapy: AIDS Clinical Trials Group Protocol A5150." HIV Clin Trials. 2011;12(1):9-23.